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Abstract
Background: Bone marrow cells induce stable mixed chimerism under appropriate conditioning of the host, mediating the
induction of transplantation tolerance. However, their strong immunogenicity precludes routine use in clinical
transplantation due to the need for harsh preconditioning and the requirement for toxic immunosuppression to prevent
rejection and graft-versus-host disease. Alternatively, embryonic stem (ES) cells have emerged as a potential source of less
immunogenic hematopoietic progenitor cells (HPCs). Up till now, however, it has been difficult to generate stable
hematopoietic cells from ES cells.
Methodology/Principal Findings: Here, we derived CD45
+ HPCs from HOXB4-transduced ES cells and showed that they
poorly express MHC antigens. This property allowed their long-term engraftment in sublethally irradiated recipients across
MHC barriers without the need for immunosuppressive agents. Although donor cells declined in peripheral blood over
2 months, low level chimerism was maintained in the bone marrow of these mice over 100 days. More importantly, chimeric
animals were protected from rejection of donor-type cardiac allografts.
Conclusions: Our data show, for the first time, the efficacy of ES-derived CD45
+ HPCs to engraft in allogenic recipients
without the use of immunosuppressive agents, there by protecting cardiac allografts from rejection.
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Introduction
Five decades ago Medawar and colleagues published an article
in Nature [1] demonstrating that transplantation tolerance can be
acquired; in these studies tolerance was strongly associated with
donor leukocyte chimerism [1,2]. Since then, it has been
appreciated that engrafting allogeneic bone marrow into irradi-
ated hosts can give the host lifelong donor-specific chimerism [3].
These hosts have hematolymphoid systems that are derived wholly
or in part from donor stem cells. Such hosts are usually
permanently tolerant of donor organ or tissue transplants. Thus,
one can transplant fully allogeneic hematopoietic stem cells and
co-transplant, for example, hearts from the hematopoietic stem
cell donor to induce lifelong donor-specific acceptance of the
transplant, without deleterious immunosuppression[4].
However, to achieve chimerism with allogeneic hematopoietic
cells, the recipient needs extreme pre-conditioning regimens that
can severely immunocompromise the patient.To avoid the severe
side effects of host pre-conditioning and the dangers related to
graft-versus-host disease associated with bone marrow or hema-
topoietic stem-cell transplantation, new data on embryonic stem
(ES) cells have sparked hope that mixed chimerism and tolerance
with minimal host-pretreatment can be achieved [5]. In addition
to the high degree of pluripotency, ES cells can generate newly-
differentiated cells that appear to have low immunogenicity, an
ideal property for allogenic transplantation. Using ES cell-derived
hematopoietic cells to achieve mixed chimerism would provide the
opportunity to accomplish immunological tolerance without the
need for harsh host pre-conditioning.
The major hindrance to exploiting ES cells has been the lack of
established protocols for efficient derivation of hematopoietic cells.
For example, earlier experiments by others revealed poor
engraftment of ES-derived hematopoietic cells in Rag-deficient
mice. Although , remarkable progress has been made in the in vitro
development of T cells from ES cells [6,7], this has not been the
case for other hematopoietic cell lineages. Further, it has remained
a challenge to obtain enough hematopoietic cells for studies on in
vitro long-term engraftment. Recent data have now revealed that
ES cells fail to engraft permanently due to their inability to self-
renew [8]. However, after transfecting ES cells with the
hematopoietic transcription factor HOXB4, cells can expand
stably in vitro and in vivo [9–11].
Interestingly, the impact of HOXB4 on human ES cells appears
to still be controversial. While Wang et al. [12] recently showed no
expansion advantage of hematopoietic cells derived from human
ES cells, Bowles and colleagues [13] saw increased expansion.
Alternatively, a combination of HOXB4 and Cdx4 led to
multilineage expansion of ES cell-derived hematopoietic cells in
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human ES cells.
More recently, recombinant TAT-HOXB4 was used to expand
hematopoietic stem cells up to 20-fold without the need for viral
gene transfection, avoiding the potential hazards of inducing
lymphoproliferative disease [15]. This property of HOXB4 can be
used to expand embryonic and adult stem cells in vitro and in vivo.
Here,we exploitHOXB4,a hematopoietictranscriptionfactor,to
facilitate the derivation of large numbers of CD45
+ cells, which were
sorted and characterized. These cells poorly express MHC class I,
CD80 and CD86, but no class II, allowing their transplantation
acrossmajorhistocompatibilitybarriers.Long-termengraftmentwas
achieved, protecting allografts from immunological rejection.
Although a number of instances of successful long-term engraft-
ment ofES-derivedHPCshave been published,nodataareavailable
yet on engraftment of these cells in immunocompetent mice. For
example, we have no information about how these newly-generated
HPCs will compete with autologous bone marrow cells for
hematopoietic niches in the recipient mice. More importantly, we
also do not know whether these cells can engraft across MHC
barriers and reconstitute bone marrow. The ability to do so, without
severe immunosuppressive regimens, would allow studies on
tolerance induction. This study focuses on the engraftment of HPCs
in immunocompetent mice and proposes a strategy that could exploit
available human ES cell lines to improve organ transplantation.
Results
HOXB4-transduced ES cells differentiate into HPCs
The derivation of multilineage hematopoietic cells from ES cells
has remained difficult, limiting their use in large-scale functional
studies. We previously showed that although we could successfully
obtain hematopoietic cells in vivo and in vitro, the cells had only a
short lifespan of up to 3–4 weeks, suggesting that they lacked self-
renewal characteristics [16].
Here, ES cells transduced with HOXB4 were analyzed for the
expression of hematopoietic markers after 26 days of differentia-
tion. The GFP
+HPCs expressed a whole range of leukocyte and
stem cell markers including CD45, CD11b, CD31; relatively low
levels of MHC class I; and no class II antigens, as we recently
reported [17]. In culture, they showed a 100- to 1000-fold greater
proliferation rate than non-transduced cells [17]. To further
characterize these cells, we sorted the CD45-expressing cells by
immunomagnetic bead separation, and measured cell purity by
flow cytometry (Figure 1a–b). In general, 70–95% of the cell
cultures had become CD45
+ before the purification procedure.
After purification, .98% of the cells were CD45
+, allowing us to
discard non-CD45-expressing cells. This procedure minimized the
danger of teratoma formation by non-differentiated cells. Since
our flow cytometric data had shown that the HPCs poorly
expressed MHC antigens [17], we wondered whether they
stimulate allogenic MRL splenocytes (H2
k). For comparison, we
used splenocytes and bone marrow cells, separately, as stimulator
cells. HPCs failed to stimulate allogenic T cells (Figure 1c), in
contrast to splenocytes and bone marrow cells, which robustly
stimulated T cells. This was consistent with poor expression of
MHC antigens and that of costimulatory molecules CD80, CD86
and ICOSL (Figure 1d).
HPCs engraft permanently in immuno-deficient Rag2
2/
2cc
2/2 and in immunocompetent mice without the use
of immunosuppressive agents
We previously utilized the Rag2
2/2cc
2/2 mice to study
whether the HPCs permanently engraft in an environment that
lacks T, B or NK cells. Our results showed that we were able to
reconstitute the Rag-deficient mice with ES cell-derived HPCs
[17]. When bone marrow from these chimeric mice was
transplanted into secondary recipients, mixed chimerism was
.80% three months post-transplantation, suggesting that the
HPCs had acquired self-renewal characteristics [17] and behaved
similar to bone marrow cells (manuscript in preparation).
Based on the low immunogenicity of the HPCs in the mixed
lymphocyte cultures, we now wondered whether the HPCs would
engraft in allogenic recipients. Allogenic MRL and control
syngeneic 129SvJ mice were sublethally irradiated and subse-
quently transplanted HPCs. Mixed chimerism was measured
28 days post-transplantation (Figure 2). The long-term degree of
mixed chimerism was similar between the immunocompetent
MRL and 129SvJ mice, with the Rag2
2/2cc
2/2 mice showing
chimerism .70%. The lack of a difference between the syngeneic
129SvJ and allogenic MRL mice suggested that the decline in the
donor cells was not due to rejection, but rather to out-competition
of the HPCs by autologous bone marrow cells. However, more
recent data from our lab suggest a role for NK cells (manuscript in
preparation).
Despite the observed decline of HPC-derived cells in peripheral
blood, 1–3% of bone marrow cells were ES-derived past 100 days,
suggesting long-term persistence of donor cells. Control MRL
mice were transplanted 129SvJ bone marrow cells that were
rejected within 14 days. Our findings suggested immunological
privilege of HPCs in the allogenic environment. This was further
supported by the observation that mixed chimerism was
comparable in two groups of MRL mice, one of which was
treated with a single dose of an anti-CD40L antibody (data not
shown). In addition, mixed lymphocyte cultures using the cells of
the chimeric animals as responder cells to donor splenocytes failed
to demonstrate any sensitization or clonal deletion of alloreactive
T cells; i.e. T cell responses were identical to those of control
animals (n=4) (data not shown). We then tracked the expression
of CD45 and class I and class II molecules on HPC-derived cells in
long-term chimeric Rag2cc
2/2 mice by gating for the GFP
expressing cells. Our results indeed showed a gradual increase of
class I expression with time, but delayed up-regulation of class II,
which appeared after day 28 (Figure 2b). We concluded that these
immunological characteristics appeared to favor HPC engraftment
in the allogenic setting.
Lineage commitment of HOXB4-transduced HPCs is
biased towards myeloid cells
It has been suggested in the past that HOXB4 may interfere
with lymphocytic cell development. Here, we determined the
percentages of CD3
+ and B220
+ lymphocytes and that of Gr-1-
expressing myeloid cells in either the 129SvJ, MRL or the Rag2
2/
2cc
2/2 mice 28 days post-transplantation. Interestingly, Gr-1-
expressing cells were predominant in all three mouse strains,
particularly in the MRL and the Rag2
2/2cc
2/2 (Figure 3). While
T and B cell development was very low in the Rag2
2/2cc
2/2
mice, higher numbers of lymphocytes (but still lower than would
be expected in bone marrow transplants) were identified in the
immunocompetent mice. Of further interest was the observation
that T cells in the 129SvJ and the MRLs were GFP
dim, consistent
with possible preferential GFP methylation in lymphocyte
progenitors. Thus, although HOXB4 appeared to impact self-
renewal and confer survival advantages to ES-derived HPCs, the
development of T and B cells was impaired. However, in a
previous study, we showed that these T cells successfully
responded to viral antigen [17], suggesting that they were
functional.
HPCs Induce Tolerance
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We therefore asked whether the chimeric MRL mice were
tolerant to the donor 129SvJ cardiac allografts. To do this, MRL
mice were sublethally irradiated and transplanted 2610
6 HPCs.
Mixed chimerism was first monitored after 14 days, and animals
with mixed chimerism greater than 10% were transplanted donor
type 129SvJ cardiac allografts. All chimeric animals accepted their
allografts (n=12) showing that established mixed chimerism was
protective (Figure 4). As expected, syngeneic allografts were
tolerated but Balb/c third party allografts were not. Balb/c third-
Figure 1. HOXB4-transduced ES cells robustly differentiate into CD45
+. HOXB4-transduced ES cells were allowed to form embryoid bodies.
The cell clusters were dismantled and subsequently treated with a hematopoietic differentiation medium. The GFP expressing cells were .70% CD45
by day 26 (A). These cells were sorted by immunomagnetic bead separation to .98% purity (B). To determine whether HPCs stimulate allogenic T
cells, MRL splenocytes were co-cultured with irradiated 129SvJ splenocytes, HPCs, or bone marrow cells. Cell proliferation was determined by
3H-
thymidine uptake. Splenocytes and bone marrow cells, but not HPCs, robustly stimulated allogenic T cells to proliferate (C). Lastly,
immunophenotyping of the HPCs revealed poor expression of co-stimulatory molecules CD80, CD86, and ICOSL (D).
doi:10.1371/journal.pone.0003212.g001
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control MRL allografts in non-chimeric animals.
To determine a possible impact of the allograft on mixed
chimerism, we measured the levels of bone marrow mixed
chimerism 40 days post cardiac graft transplantation. These
results, shown in Figures 5a–c, demonstrated robust mixed
chimerism in the bone marrow as measured by flow cytometry.
At this point, peripheral blood mixed chimerism was generally
,5%. By day 100, however, mixed chimerism was undetectable in
peripheral blood despite the fact that the recipient animals were
tolerant to the allografts. We therefore sacrificed the mice and
measured donor cells in the spleen and bone marrow. All six
animals in this series showed a distinct population of CD45
+ GFP
+
(Figure 5d). When further stained, the cells were found to be
CD117
+Sca-1
+. Put together, about 1.5% of bone marrow cells
and ,0.2% of splenic cells were GFP
+ and therefore HPC-derived
(Figure 5e). Both the spleen and peripheral blood showed much
lower cell numbers than those detected in bone marrow. Thus,
HPC-derived cells persisted in the bone marrow, possibly
maintaining tolerance to the graft by supplying donor cells into
the blood circulation. These results reinforce our notion that the
decrease in mixed chimerism in the immunocompetent mice, but
not in the Rag2
2/2cc
2/2 mice, is likely due to competition for
space by the recovering autologous bone marrow cells. In ongoing
experiments, we are studying whether natural killer cells play a
role in the engraftment of HPCs in immunocompetent mice.
Immunohistology of tolerated allografts
To determine the histology of the allografts, we sacrificed our
transplanted animals on either day 40 or day 100 post-transplan-
tation. As controls, syngeneic grafts at 100 days post-transplantation
and acutely rejected allografts harvested 13 days post-transplanta-
tion were examined after H & E staining (Figure 6). As expected,
acutely rejected allografts were massively infiltrated by mononuclear
cells, whereas tolerant allografts were free of infiltrating cells at both
40 and 100 days post-transplantation. In addition, there was no
evidence of intimal thickening as a sign of chronic rejection. The
results were unexpected, as our animals were not treated with any
immunosuppression other than the sublethal irradiation pre-HPC
infusion, either pre- or post-transplantation. To rule out that this
graft tolerance was not due to the irradiation alone, a control group
was similarly transplanted after irradiation. All animals uniformly
rejected by day 13, showing no difference to the non-irradiated
controls that rejected in similar fashion.
Induction of graft tolerance is not mediated by a deletion
of alloreactive T cells, but rather is associated with
intragraft FoxP3
+CD4
+ T cells
We wondered what mechanism was responsible for maintaining
graft tolerance. One of the assays widely used in the literature is
the application of splenocytes from tolerant animals as responder
cells in a 4-day mixed lymphocyte culture. Balb/c splenocytes
were used as third-party responder cells assuming that these would
induce the same degree of T cell proliferation in tolerant and
control animals. Surprisingly, there was no difference between our
tolerant and control animals in the degree of T cell proliferation
(data not shown). Thus, the frequency of alloreactive T cells
towards the donor type alloantigen was the same in both tolerant
and non-tolerant animals. This finding suggested lack of clonal
deletion of alloreactive T cells.
We next stained for CD4
+ cells in the tolerated and rejected
allografts. Isolated CD4
+ cells were detected in the tolerated
allografts 40 days post-transplantation (Figure 7a). In contrast,
rejected allografts (13 days post-transplantation) were massively
infiltrated with mononuclear cells including a much higher
number of CD4-positive cells (Figure 7b). To detect regulatory
T cells, we co-stained our sections by immunofluorescence for
FoxP3 and CD4-expressing cells. FoxP3 expressing cells that were
CD4
+ were readily detected in tolerant allografts (Figures 7c–e).
Similar stains on control syngeneic grafts and rejected allografts
revealed only CD4
+FoxP3
2 cells (Figures 7f and 7g, respectively).
To quantitate these Tregs, we counted FoxP3
+CD4
+ cells in all
sections. Grafts from tolerant animals had an average of 17
positive cells per 120 CD4
+ cells on histological sections, compared
to less than 1 in both the rejected or the syngeneic controls,
suggesting a role for Tregs in HPC-induced tolerance. To more
definitively address the role for Tregs in this model, depletion
studies are ongoing.
Lastly, we isolated CD4
+ cells from the splenocytes of the
tolerant and the rejecting mice, and performed IL-2 ELISPOT
analysis. ELISPOTS in tolerant animals were similar to those from
control mice (p.0.05) but significantly lower than those in
sensitized mice, p,0.05 (Figure 7h). These observations confirmed
our results of the proliferation assays which failed to show any
evidence of activated T cells in tolerant animals. However, since
the ELISPOTS were nearly identical to our controls, they support
lack of clonal deletion of alloreactive T cells. Responses to third-
party Balb/c mice were similar in tolerant, sensitized and control
non-transplanted mice showing specificity to donor-type alloanti-
gen as would be expected.
Discussion
ES cells provide new opportunities for developing and
establishing new treatments, including transplantation tolerance
Figure2.HPCsinducehematopoieticmixed chimerism.(A) 2610
6
HPCs were transplanted in sublethally irradiated MRL, Rag2
2/2cc
2/2 or
129SvJ 8–12 week old mice. Mixed chimerism was monitored by
measuring by flow cytometry GFP-expressing CD45
+ cells over 100 days.
(B) The expression of MHC antigens by the chimeric hematopoietic cells
was determined by flow cytometry in the Rag2
2/2cc
2/2 mice. Although
the donor cells maintained a high CD45 expression from the start, there
was a gradual increase of both class I and class II antigens.
doi:10.1371/journal.pone.0003212.g002
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antigens, poor expression of co-stimulatory molecules and lack of
T cells that can trigger graft-versus-host reaction. For these
reasons, conditioning recipients of allogenic ES cell-derived HPCs
could potentially be safer and less rigorous than conditioning
recipients of bone marrow cells.
The biggest challenge, however, has been overcoming the
difficulty of generating sufficient cell numbers of ES cell-derived
HPCs. Earlier studies by Potocnik et al. [18,19] showed mild
engraftment of ES-derived cells in Rag-deficient mice. Such
successful experiments remained rare until the description of
HOXB4, a hematopoietic transcription factor that confers self-
renewal properties to ES-derived cells [9]. Additionally, strategies
have been described in the literature [20,21], unfortunately, these
have remained difficult to reproduce.
Here, we sought to study whether ectopically expressed HOXB4
allows the differentiation ofEScells into HPCsthatcan be utilized to
confer transplantation tolerance. Indeed, HPC proliferation was
several hundred-fold higher than in non-transduced HPCs.
Importantly, these cells expressed CD45, with smaller subpopula-
tions expressing the important hematopoietic markers CD117 and
Sca-1, suggesting that these cells may have the potential to populate
bone marrow and eventually replenish senescent peripheral blood
hematopoietic cells. Most recently, we used HOXB4-expressing
HPCs to reconstitute Rag-deficient mice, and showed robust mixed
chimerism in these mice [17]. Although a number of groups have
already looked at the engraftment of ES-derived HPCs in Rag2
2/
2cc
2/2 mice, there are no reports on HPC engraftment in either
syngeneic or allogenic immunocompetent mice. This is important as
the poor immunogenicity of these cells could be exploited for
transplanting across MHC barriers with minimal conditioning of the
host. Indeed, HPCs failed to stimulate allogenic T cells in
proliferation assays, in contrast to splenocytes and bone marrow
cells. We therefore transplanted Rag2
2/2cc
2/2 mice, allogenic
MRL mice and syngeneic 129SvJ mice with 2610
6 HPCs after
sublethal irradiation. In Rag2
2/2cc
2/2 mice, long-term engraft-
ment of donor-derived HPCs was greater than 70% mixed
chimerism. In contrast, engraftment in MRL mice and 129SvJ mice
Figure 3. Poor T and B cell development in HPC-derived hematopoietic cells. Using flow cytometry, chimeric 129SvJ, MRL, and Rag2
2/2cc
2/2
mice were analyzed for donor cells at 28 days post-transplantation. In all three strains, Gr-1
+ cells were the predominant sub-population with lower cell
numbers of B220- and CD3-expressing B and T cells, respectively. The percentages are calculated within the GFP
+ population.
doi:10.1371/journal.pone.0003212.g003
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difference was largely strain-dependent, it also reflected the fact that
in the Rag2
2/2cc
2/2 mice hematopoietic space was greater than in
the immunocompetent mice. On long-term monitoring, HPC-
derived hematopoietic cells remained detectable in both the
allogenic and syngeneic mice, albeit declining with time. Despite
the allogenic barrier, the MRL mice showed a similar pattern as the
syngeneic recipients, suggesting that the engraftment was less likely
to be regulated by adaptive immunological factors. The increase in
expression of donor type MHC antigens on the HPC-derived
hematopoietic cells was gradual. While the HPCs showed low class I
expression from the beginning, gradually increasing over 60 days to
.80% positive, class II antigens were first detectable at about
28 days post-transplantation.
Previously we had reported that lymphoid cell development in the
Rag2
2/2cc
2/2 mice was poor [17]. We speculated that this could
be due tothe poordevelopment of thelymphoid tissues inthese mice
rather than the inherent inability of the HPCs to develop into
lymphoid cells. Although we wereableto now detect more distinct T
and B cell populations in the transplanted immunocompetent MRL
and 129SvJ mice, the numbers of lymphoid cells remained far less
than would be expected after bone marrow transplantation.The Gr-
1 expressing cells were the dominant population. This observation
has been made before and appears to possibly be an influence of the
overexpression of the HOXB4 gene [10,17]. However, co-
expression of cdx4 and HOXB4 in ES cells improved the generation
of T and B cells [14]. This is an interesting observation as cdx4 is
upstream and may therefore regulate HOXB4, reducing its negative
impact on lymphopoiesis.
Once long-term mixed chimerism was established, we deter-
mined the influence of donor cells on the ability of the host’s T
cells to respond to alloantigen. This was first tested by using mixed
lympocyte cultures. Although the T cells of chimeric animals
responded to alloantigen, the response was similar to that of non-
chimeric control animals, suggesting that these cells did not appear
to lead to deletion of alloreactive T cells. We wondered whether
this lack of stimuli could be observed in a transplantation model.
Therefore, chimeric MRL mice were transplanted with donor-
type 129SvJ cardiac allografts and left untreated. Third-party
Balb/c cardiac allografts were transplanted in chimeric MRL mice
to test for specificity. Long-term engraftment of the allogenic
129SvJ allografts in the MRL mice was observed in all chimeric
recipients, but not that of third-party Balb/c allografts. These
results were not expected, as recipient mice had only been
sublethally irradiated and left otherwise untreated. This is the first
time that in vitro generated HPCs were transplanted and used to
establish long-term engraftment in allogeneic immunocompetent
mice, resulting in the protection of donor type grafts from
immunological rejection. We and colleagues previously used non-
differentiated ES cell-like cells in a rat model to protect them from
rejection [5]. Those experiments were, however, hampered by
teratoma formation, low efficiency in engraftment, and lack of full-
lineage mixed chimerism. In addition, they proved irreproducible
in mice. To avoid those pitfalls here, we show that pre-
differentiation and pre-sorting of HPCs avoids formation of
teratomas. Further, the HPCs derived here are immunologically
well-defined, allowing mechanistic studies.
Of further interest was the long-term monitoring of mixed
chimerism after the cardiac transplants. By 40 days post-transplan-
tation, peripheral mixed chimerism was less than 3% in all animals,
but much higher in the bone marrow. The percentages of these cells
continued to decrease and were maintained at about 1.5% in the
bone marrow past day 100. These results allow us to conclude that
failure to detect donor cells in peripheral blood of previously
chimeric animals may not truly reflect the immunological status of
these animals. Bone marrow appears to be the site where donor cells
reside long-term, supplying peripheral blood with circulating donor
hematopoietic cells that can maintain tolerance. We also recently
showed that HPCs populated the thymus of Rag2
2/2cc
2/2
recipient mice [17], which we believe is critical in tolerance
induction. Here, we confirmed these results by detecting HPC-
derived cells in the thymuses of both allogenic and syngeneic mice
(data not shown). The percentage of the HPCs was, however, less
than 1% but consistent, suggesting that the cells migrate into the
thymus, possibly impacting the T cell repertoire of recipient mice.
In line with our contention of tolerance induction, the histology of
the explanted allografts showed very low infiltration by mononuclear
cells at day 40 and day 100. On histochemical staining, we noted a
higher degree of CD4-expressing T cells compared to CD8
+ cells. A
higher percentage of Tregs was detected in tolerant animals than in
controls, which is consistent with tolerance.
Studies on intragraft Tregs are very limited. In a non-human
primate study, Haanstra et al. reported that within the graft-
infiltrating lymphocytes, accepted allografts did not have greater
numbers of Tregs than rejecting allografts [22]. Our results differ,
which perhaps reflects the protocols used and the organ
transplanted, as these investigators used a renal transplant model
in a large preclinical model. These observations, coupled with the
fact that we found no evidence of T cell deletion, suggest that
HPCs may induce a state of non-responsiveness by inducing
Tregs. We previously discussed that ES cells secrete TGF-b [16].
Thus, this property, in addition to the poor expression of MHC
antigens and low expression of co-stimulatory molecules on the
HPCs, might contribute to Treg development. Interestingly, when
we looked at the splenocytes in these mice and compared them to
controls, we were not able to detect a significant difference in the
numbers of Tregs, suggesting that in the transplant model, Tregs
may be within the graft-infiltrating population where they could
regulate infiltrating host T cells.
Figure 4. ES-derived HOXB4-expressing HPCs induce immuno-
logical tolerance to donor type cardiac allografts. A) Treatment
protocol: MRL recipient mice were transplanted HPCs 14 days prior to
transplantation of cardiac allografts which was performed between
days 0 and 7. Cardiac function and survival were monitored by daily
abdominal palpations. B) Graft survival: Chimeric MRL recipient mice
tolerated donor type cardiac allografts, but not Balb/c third party
allografts. Non-chimeric MRL mice acutely rejected allografts within
13 days. Syngeneic grafts were additionally used as controls.
doi:10.1371/journal.pone.0003212.g004
HPCs Induce Tolerance
PLoS ONE | www.plosone.org 6 September 2008 | Volume 3 | Issue 9 | e3212Most recently, Robertson et al. reported that embryoid bodies
derived from ES cells were immune privileged, requiring minimal
conditioning to engraft across MHC barriers [23]. Despite the fact
that embryoid bodies are a poorly-defined mixture of all three
germinal layers, their data are in agreement with our findings.
However, here, we used a well-defined hematopoietic cell
population derived from ES cells, and we showed the kinetics of
their MHC expression. The delayed and gradual upregulation of
MHC antigens contributed to the immune privilege of these cells
in the allogenic setting. A combination of our current protocol
with a myeloablative treatment approach might further improve
HPC engraftment in immunocompetent mice.
Materials and Methods
ES cell lines and maintenance in culture
The CCE cell line transduced with the HOXB4 gene is a
generous gift from Dr. Hannes Klump (Hannover Medizinische
Hochschule, Germany), and was previously described by Schiedl-
meier et al. {Schiedlmeier, 2003 3370/id} and more recently by
us [17]. The expression vector contained the cDNAs coding for a
potential fusion protein containing the GFP (EGFP), the 2A
esterase of foot-and-mouth disease virus (FMDV), and HOXB4
with an additional N-terminal hemagglutinin (HA) epitope tag
(eGFP2AHOXB4). The 2A moiety mediates cotranslational
separation of the growing polypeptide chain [25]. ES cells
expressing EGFP were FACS-sorted and cultured. ES cells were
maintained in culture according to standard conditions as we have
previously described in detail [16,26]. Briefly, ES cells were kept in
standard ES cell medium containing leukemia inhibitory factor
(LIF) which prevents cell differentiation. The cells were main-
tained on gelatinized tissue culture dishes. The culture medium
was changed every 1–2 days and passaged every 2–3 days.
Derivation and culture of HPCs
To derive HPCs, LIF was omitted from the culture media of
HOXB4-transduced CCE cells to allow embryoid body formation.
After five days, EBs were dissociated and seeded in serum-free
medium supplemented with 100ng/ml murine stem cell factor (R
& D), 10
26M dexamethasone (Sigma-Aldrich), 40 ng/ml IGF-1
(Promega), 2 ng/ml IL3, 5 ng/ml IL-6, and 10 ng/ml mflt-3L. In
this medium, the HOXB4 gene is activated and stoichiometrically
expressed at a 1:1 ratio with GFP, so that the cells turn green as
they become hematopoietic. The green fluorescence offers an
excellent marker for monitoring the differentiated cells by flow
cytometry post-transplantation. Cell density was kept between 2
and 4610
6 cells per ml.
Mixed cell cultures
To determine whether HPCs stimulate alloreactive T cells, 5610
5
129SvJ CD45
+ HPCs, splenocytes or bone marrow cells were
irradiated with 20 cGy and plated into 96-well microtiter plates in
Figure 5. Tolerant mice maintain bone marrow mixed chimerism post-transplantation. The percentage of donor-derived hematopoietic
cells in bone marrow cells of recipient tolerant mice was monitored using flow cytometry. A robust CD45
+ cell population was detected (A) of which
a large portion was Gr-1
+ (B). Interestingly a small proportion of these cells was CD117-expressing, suggesting the presence of a truly bone marrow-
resident stem cell population (C). At day 100 post-transplantation, the percentage of donor cells had decreased (D). Altogether, at day 100 post-
transplantation, donor cells were hardly detectable in peripheral blood, 0.5–1% in the spleen, and 1–2% in the bone marrow (E, n=6).
doi:10.1371/journal.pone.0003212.g005
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streptomycin. An equal number of MRL respondersplenocytes were
added and the cells cultured for 48 h before pulsing. After another
16 h, the cultures were harvested and H
3-thymidine uptake
measured in a gamma counter as we previously reported [27]. For
measuring responses of chimeric or transplanted animals, spleno-
cytes from these animals were used as responder animals similarly.
Transplantation of HPCs and monitoring of HPC-derived
hematopoietic cells
We previously established that 2610
6 non-differentiated ES cells
per mouse are sufficient to induce mixed chimerism [16]. Here,
2610
6 GFP
+CD45
+ HPCs or bone marrow cells were infused into
the supra-orbital vein of sublethally irradiated mice. Recipient
animals were the allogenic MRL (H2
k), the immunodeficient
Rag2
2/2cc
2/2 (Taconic) mice or the syngeneic 129SvJ (H2
b)m i c e .
The MRL and 129SvJ mice were originally purchased from Jackson
Laboratory and bred at the Veterans Affairs Medical Center inIowa
City.Inaddition, themicewereinfused with 5610
5 autologousbone
marrow cells [10]. Mixed chimerism was monitored at 14, 28, 56,
and100 dayspost-transplantation.Venousbloodwasdrawnatthese
time points and the cells stained with PE-conjugated antibodies
against MHC class I, class II, CD45, CD3, B220 or Gr-1, which
represent antibodies against myeloid and lymphoid markers. The
GFP co-expression indicated HPC-derived cells. All animal
experiments were approved by the Animal Care Board of the
Veterans Affairs Medical Center Iowa City.
Organ transplantation
Mice donating cardiac allografts were 8–12 week-old 129SvJ mice
(H2k
b), and the recipients were allogenic MRL mice (H2K
k)o ft h e
same age. Cardiac transplantations were performed as previously
reported {Corry, 1973 3376/id}. Cardiac function was monitored
by abdominal palpations. Acutely rejected allografts ceased to beat
and generally were larger, indicating cardiomyopathy.
Post-transplant monitoring of donor cells, H & E staining
and immunostaining of cardiac allografts
Acutely rejected allografts were harvested at day 13 post-
transplantation. Syngeneic allografts were harvested at 100 days
post-transplantation. Allogenic allografts in chimeric mice were
harvested on either day 40 or day 100-post transplantation. At
these time points, mixed chimerism was monitored by flow
cytometry in venous blood, spleen and bone marrow. Cells were
stained for CD45, B220, CD3, CD117, and Sca-1. Additionally,
splenocytes of recipient animals were used as responder cells in
mixed lymphocyte reactions and ELISPOT to determine
responses to donor alloantigen. Paraffin sections were fixed
according to standard procedure and stained with hematoxylin
and eosin. To study infiltration of allografts, frozen sections were
stained with peroxidase-conjugated antibodies against either CD4
or CD8 as recommended by the manufacturer (BD Biosciences,
San Diego, CA). For studies on Tregs, FITC-conjugated anti-CD4
and PE-conjugated anti-FoxP3 antibodies (BD Biosciences) were
used for fluorescence staining. Immunofluorescent sections were
analyzed using a Bio-Rad Radience 2100 MP Confocal/
Multiphoton Microscope at the Central Microscopy Research
Facility at The University of Iowa.
IL-2 ELISPOT Assay
Immunomodulation of alloresponses in chimeric animals was
determined using the IL-2 ELISPOT assay as instructed by the
manufacturer (BD Biosciences). Briefly, ELISPOT plates were
coated with capture Ab at the prescribed concentration overnight
at 4uC. Plates were subsequently washed and blocked with RPMI
1640 medium supplemented with 10% FCS for 2 h at room
temperature. CD4
+ T cells sorted by immunomagnetic beads
from splenocytes of animals tolerant to donor-type cardiac
allografts were plated at 10
6 cells/well. Positive controls were
CD4
+ T cells isolated from animals prior sensitized with two
immunizations of 3610
7 donor splenocytes over 10 days.
Figure 6. HPC-induced mixed chimerism preserves organ architecture post-transplantation. Transplanted syngeneic and allogenic
animals were sacrificed at either 40 or 100 days post-transplantation and the histology of the grafts studied after H & E staining. These grafts showed
preservation of the muscle architecture and lack of mononuclear cell infiltration in the syngeneic and tolerant grafts, but massive tissue destruction in
the acutely rejected control grafts.
doi:10.1371/journal.pone.0003212.g006
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Plates were incubated at 37uC overnight, washed, and coated
with detection Ab for 2 h at room temperature. Plates were
subsequently washed, coated with avidin-peroxidase for 1 h at
room temperature, washed again, and developed by addition of
3-amino-9-ethylcarbazole substrate. Developed plates were dried
overnight and analyzed with ImmunoSpot software. Statistical
analysis was performed using the Graphpad-Prism software
package, Version 4.0.
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Figure 7. Tolerance induction is accompanied by the presence of CD4FoxP3
+ T cells in the tolerated allografts but not in the
syngeneic control grafts. A) & B) Frozen sections of tolerated cardiac allografts were stained for CD4 on day 40 post-transplantation using a
peroxidase-conjugated antibody (A). A section from an acutely rejected graft was used as control (B). Positively stained cells are stained brown. C)–
H) To determine whether any of the CD4
+ T cells were Tregs, frozen sections were co-stained for CD4 (FITC) and FoxP3 (PE). In the tolerant allograft,
FoxP3
+ cells (C) and CD4
+ (D) cells were detected, which overlapped when merged (E) suggesting that the CD4
+ cells expressed FoxP3. In contrast,
none of the syngeneic or rejected allografts showed any FoxP3-expressing cells, as reflected by the merged stains of both FoxP3 and CD4 stains in F
and G, respectively. (Magnification for C–E: 6600; magnification for F and G:6200.)H) Lastly, splenic CD4
+ T cells from these tolerant animals were
used as responder cells in an ELISPOT assay that measured IL-2 production. Controls were animals pre-sensitized with two separate IP injections of
donor splenocytes and non-transplanted control animals. The sensitized animals showed a higher number of IL-2 spots against the donor
splenocytes, as expected. However, the control non-sensitized and tolerant animals showed equal numbers of spots, suggesting that indeed the
tolerant animals had no activated alloreactive T cells. All three groups of animals responded equally to third-party Balb/c splenocytes.
doi:10.1371/journal.pone.0003212.g007
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